Physician profile
Ketsia Aurelien
NPI 1598247314
$1,215.95
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.25 · 2022: $1,029 · 2023: $41.87 · 2024: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $166.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $264.15 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $174.04 | 2022-2024 | Breztri |
| Horizon Therapeutics Plc | $160.44 | 2022-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.35 | 2022 | |
| Merck Sharp & Dohme LLC | $66.14 | 2022 | |
| Fresenius USA Marketing, INC. | $64.89 | 2022 | |
| Mallinckrodt Hospital Products INC. | $62.93 | 2022 | |
| Lilly USA, LLC | $56.76 | 2022 | |
| Xeris Pharmaceuticals, INC. | $46.31 | 2022 | |
| Alnylam Pharmaceuticals INC. | $43.74 | 2022 | |
| Janssen Pharmaceuticals, INC | $39.46 | 2021-2022 | |
| Grt US Holding, INC. | $22.03 | 2022 | |
| Aurinia Pharma U.S., INC. | $18.33 | 2022 | |
| Amgen INC. | $17.27 | 2022 | |
| Corcept Therapeutics | $16.64 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $16.21 | 2022 | |
| Genzyme Corporation | $16.17 | 2022 | |
| Neurocrine Biosciences, INC. | $16.09 | 2023 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ketsia Aurelien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.